» FDA Accepts Streamlined Phase 3 Development Plan For Q8003IR 'Dual Opioid' Pain Therapy
QRxPharma Limited (ASX: QRX; OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS)…